Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib Basel, 4 July 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved alectinib for the treatment of people living with non-small cell lung cancer (NSCLC) […]
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer Basel, 2 July 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in […]
Avastin is the first biologic medicine to receive a CHMP positive opinion for the most difficult to treat form of ovarian cancer The positive opinion is based on a pivotal phase III study showing that the addition of Avastin to chemotherapy reduced the risk of disease worsening or death by 62 percent Basel, 27 June […]
June 2, 2014 – CHICAGO – New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used alone or in combination – fight cancer by activating and amplifying the body’s immune response to the disease. […]
Large Phase III Trials Establish New Standards of Care, Affirm Effectiveness of Commonly Used Targeted Treatment Options June 1, 2014 – CHICAGO – Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in […]
ASCO Annual Meeting Features Key Advances in Ovarian, Lung and Thyroid Cancers and Leukemia May 31, 2014 – CHICAGO – Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). […]
The U.S. Food and Drug Administration (FDA) has granted first Breakthrough Therapy Designation in bladder cancer for MPDL3280A Basel, 31 May 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a Phase I open-label study that showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) shrank tumours (overall response rate) in 43 percent (13/30) […]
New Research Shows Value of “Less Is More” Treatment Strategies and Earlier Palliative Care, Supports New Fertility Preservation Technique for Women With Breast Cancer May 30, 2014 – CHICAGO – Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects […]
Plan Eases Financial Burden for Members in Crisis PORTLAND, Ore. MAY 28, 2014 – LifeMap Assurance Company has launched a new cancer-specific critical illness plan. LifeMap Cancer Care helps members manage a life-altering cancer diagnosis that could affect their income and their families’ way of life. As the newest addition to the LifeMap critical illness […]
ASCO Releases More Than 5,000 Studies for Its 50th Annual Meeting May 13, 2014 – ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) today highlighted results from five major studies to be presented at ASCO’s 50th Annual Meeting, May 30-June 3, 2014, in Chicago. The research found that hormone therapy can be safely delayed following […]